about
NVP-LDE225, a potent and selective SMOOTHENED antagonist reduces melanoma growth in vitro and in vivoMain roads to melanomaSentinel lymph node biopsy followed by lymph node dissection for localised primary cutaneous melanomaSentinel lymph node biopsy followed by lymph node dissection for early cutaneous melanomaTWIST1 is an ERK1/2 effector that promotes invasion and regulates MMP-1 expression in human melanoma cellsFOXD3 regulates migration properties and Rnd3 expression in melanoma cellsTreatment of metastatic melanoma: an overviewCancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisionsVemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic MelanomaNovel Drugs and Combination Therapies for the Treatment of Metastatic MelanomaUnderstanding Melanocyte Stem Cells for Disease Modeling and Regenerative Medicine ApplicationsVoriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipientsContinuing to illuminate the mechanisms underlying UV-mediated melanomagenesisLocal anesthetic thoracoscopy for the diagnosis of metastatic pleural melanoma originated from oral malignant melanoma: case report and commentsNRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma.Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development StrategyEmerging technologies for studying DNA methylation for the molecular diagnosis of cancerReduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasisBurden of illness for metastatic melanoma in Canada, 2011-2013The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cellsComputational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma CancerA novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent mannerFAK competes for Src to promote migration against invasion in melanoma cells.Toward in vivo biopsy of melanoma based on photoacoustic and ultrasound dual imaging with an integrated detector.Extracutaneous melanomas: a primer for the radiologist.GLI2-mediated melanoma invasion and metastasis.Rnd3 regulation of the actin cytoskeleton promotes melanoma migration and invasive outgrowth in three dimensionsExtracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging.MERTK receptor tyrosine kinase is a therapeutic target in melanoma.Discrepant alterations in main candidate genes among multiple primary melanomasToward predicting metastatic progression of melanoma based on gene expression data.CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.Nck2 promotes human melanoma cell proliferation, migration and invasion in vitro and primary melanoma-derived tumor growth in vivoData-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells.The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cellsMicroRNA-221 and -222 pathway controls melanoma progression.Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
P2860
Q21132689-BD112101-7523-402C-9742-78E1B57D3BB2Q21245465-3ABAC375-DF67-4BA8-AFDA-15121288F0F5Q24187945-76E96E73-FB1F-4830-8136-4CDFAAA162AEQ24201860-CEE79FA9-87C4-46BA-8AF2-4DC84927F5E5Q24594566-C7C92510-BE20-414D-8BB0-7759095CCFCAQ24633339-02D901DB-9F0E-4DC5-A45B-D9765F0164E9Q24642384-62633DD8-ED71-4CE8-86CD-971FB0E9CE57Q26261171-83712847-D5DD-4286-9E46-52AA84558CA2Q26771941-CCCA0FC5-38D8-401D-9829-699B2DD459B8Q26772015-45295034-91C0-433A-B29F-DA477AB6491BQ26772030-1A3F31A6-F40D-4A9A-87B8-4E64EC5DB7B3Q27012442-B3829B8B-6BED-4856-96DB-72AEF620E924Q27026261-E36439BE-763B-413A-88A4-A14A8709764BQ27303917-9C622367-56A4-45EF-B1B7-F2AE6252E53EQ27852445-32D5AA40-8FE8-4994-BE7D-B0FAB9160B43Q27853026-1BFC9657-D62A-4F41-AB5A-8B8C6E00485DQ28076840-E9FFA70C-2237-4028-B416-EBE8471F7259Q28087759-3A777233-976C-4DCE-AFFE-5F6C8A593918Q28257114-4C2142DD-CB1F-4C6D-BC69-0FFE63044882Q28354125-8D437030-3950-44D4-8C63-7F7EC16F920AQ28476737-AC74F9EE-053C-4214-A276-0E6451D5809FQ28484515-66E47D90-01F3-400F-94E9-161201AD3A37Q28551002-38E9ED4E-C574-4DB9-8C4B-9E65D7E2BD14Q28817145-54135A64-6ECA-426D-BB4C-263A5365A3DBQ30009333-9019BFE2-D5FD-4B41-A030-7DD5DC88D284Q30388404-36166783-8D88-4009-A6BD-8F3AC5E725DEQ30397680-2CD0D8A1-CA99-4075-9F64-254A6663EC4FQ30431168-5AAB5A00-B686-4EB5-9CCB-2F29B4B8D2BCQ30486572-D1D98442-359B-47A6-92BC-297F4744BFB4Q30496848-EC29830D-5473-43CA-BA62-F909275850DAQ30539324-4ED6F025-2175-4F1A-9576-C7B0D0A586AAQ30578299-97F1E404-6395-4D06-A081-6996561B53D6Q30924798-363E1BAA-5308-4F0A-A7EC-7707608239F8Q30988544-511DFD89-B1A4-4782-BF5D-56DCEE00EB4AQ31033276-13FCFE64-FCBD-4AAE-A440-AE094CA008EDQ31171102-7BAC8418-DEEE-45F1-B305-819369F0B3C5Q33372937-A4C415F6-727A-42CB-8CA1-A4FA607DBEE4Q33382465-3BA102F7-5EBA-45C4-AE6B-145321FF4445Q33407216-D947A291-E73F-4E14-99AB-A28F6E380271Q33414272-541A15C1-B0E1-4BF9-9C2A-B661060D1222
P2860
description
im Juli 2006 veröffentlichter wissenschaftlicher Artikel
@de
наукова стаття, опублікована в липні 2006
@uk
name
Melanoma
@en
type
label
Melanoma
@en
prefLabel
Melanoma
@en
P356
P1476
Melanoma
@en
P2093
Arlo J. Miller
Martin C. Mihm
P356
10.1056/NEJMRA052166
P407
P577
2006-07-06T00:00:00Z